Raymond James Financial Inc. Buys 207,528 Shares of ADMA Biologics Inc $ADMA

Key Points

• Raymond James Financial Inc. increased its stake in ADMA Biologics by 18.7% in the first quarter, owning over 1.3 million shares valued at approximately $26.2 million.
• Multiple institutional investors are showing significant interest, with Envestnet Asset Management boosting its position by 68% during the fourth quarter.
• ADMA Biologics reported a solid quarterly EPS of $0.15, exceeding analysts' expectations, and achieved a 13.8% year-over-year revenue increase with $121.98 million in revenue.

Raymond James Financial Inc. boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 18.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,319,803 shares of the biotechnology company's stock after acquiring an additional 207,528 shares during the quarter. Raymond James Financial Inc. owned 0.56% of ADMA Biologics worth $26,186,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ADMA. Envestnet Asset Management Inc. lifted its position in shares of ADMA Biologics by 68.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 60,004 shares of the biotechnology company's stock worth $1,029,000 after buying an additional 24,293 shares in the last quarter. Mariner LLC bought a new position in shares of ADMA Biologics during the 4th quarter worth approximately $573,000. Dimensional Fund Advisors LP lifted its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of ADMA Biologics by 4.7% during the 4th quarter. MetLife Investment Management LLC now owns 136,212 shares of the biotechnology company's stock worth $2,336,000 after buying an additional 6,060 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of ADMA Biologics by 1,029.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 39,236 shares of the biotechnology company's stock worth $673,000 after buying an additional 35,763 shares in the last quarter. Institutional investors own 75.68% of the company's stock.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 455,621 shares of company stock worth $9,461,633. Corporate insiders own 3.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Raymond James Financial lifted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat.com, ADMA Biologics has an average rating of "Buy" and an average price target of $27.67.

ADMA Biologics Stock Performance

ADMA Biologics stock traded up $0.13 during mid-day trading on Thursday, reaching $17.38. The company's stock had a trading volume of 2,100,631 shares, compared to its average volume of 3,110,884. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company has a market capitalization of $4.15 billion, a P/E ratio of 20.21 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The firm's fifty day moving average price is $17.79 and its two-hundred day moving average price is $18.88.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 EPS. Sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.